Journal Article Summary
The article investigates the effects of semaglutide, a medication used for weight management, on body composition in adults with overweight or obesity. This topic is significant because central obesity is linked to a higher risk of developing cardiometabolic diseases, and understanding how weight loss affects body composition can help in managing these health risks. The study specifically looks at how semaglutide influences fat and lean body mass, which is important for maintaining overall health and physical function.
In the STEP 1 study, 1,961 adults with a body mass index (BMI) of 27 or higher, and at least one weight-related health issue, were randomly assigned to receive either semaglutide or a placebo for 68 weeks, alongside lifestyle changes. The analysis focused on 140 participants who underwent dual energy X-ray absorptiometry (DEXA) scans to measure changes in body composition. The results showed that those taking semaglutide experienced a significant weight loss of 15% compared to 3.6% in the placebo group, along with reductions in total fat mass and visceral fat mass. Although there was a decrease in total lean body mass, the proportion of lean mass relative to total body weight increased, indicating a favorable change in body composition.
However, the study has limitations, including a relatively small sample size for the analysis and the short duration of the intervention. Patients should be aware that while semaglutide can lead to weight loss and changes in body composition, it may not be suitable for everyone. It is important for individuals considering this treatment to discuss potential benefits and risks with their healthcare provider, especially regarding how it fits into their overall health plan and any underlying conditions they may have.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Wilding John P H, Batterham Rachel L, Calanna Salvatore, Van Gaal Luc F, McGowan Barbara M, Rosenstock Julio, Tran Marie T D, Wharton Sean, et al.. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society 2021. DOI: 10.1210/jendso/bvab048.030. PMCID: PMC8089287.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
